PMID- 37340230
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230801
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 14
IP  - 9
DP  - 2023 Sep
TI  - Perceived Future Outcomes of Unsuccessful Treatment and Their Association with 
      Treatment Persistence Among Type-2 Diabetes Patients: A Cross-Sectional Content 
      Analysis.
PG  - 1437-1449
LID - 10.1007/s13300-023-01433-1 [doi]
AB  - INTRODUCTION: Despite the known strong association between patients' knowledge of 
      outcomes of type 2 diabetes mellitus (T2DM) and treatment persistence, this 
      knowledge in this patient population requires further clarification. The aim of 
      our study was to reveal the perception of unsuccessful treatment outcomes among 
      patients with T2DM and its association with treatment persistence by analysing 
      answers to open-ended questions. METHODS: In this cross-sectional study, 106 
      patients with T2DM who lived in Fukushima Prefecture, Japan, had a medical record 
      in the Fukushima National Health Insurance Organisation database and had no 
      cognitive problems were enrolled by purposive sampling. Treatment status was 
      defined as "non-persistent" when a participant's treatment medical record was 
      absent for a continuous period of >/= 6 months; otherwise, it was referred to as 
      "persistent". We asked about the possible future problems of untreated T2DM, 
      inductively classified the open answers into 15 codes and then statistically 
      examined the association between these codes and treatment persistence using 
      logistic regression analysis adjusted for age and sex. RESULTS: Persistent 
      treatment was prevalent among participants who mentioned the code "treatment", 
      which encompasses the terms that indicated invasiveness, such as dialysis, 
      insulin injection, and shots (odds ratio 4.339; 95% confidence 
      interval 1.104-17.055). CONCLUSION: Persistent treatment was prevalent among 
      patients with T2DM who mentioned the code "treatment", suggesting that these 
      patients may anticipate a threat due to the invasiveness of diabetes and thus 
      participate in persistent treatment to avoid this threat. Healthcare 
      professionals should provide appropriate information and supportive conditions to 
      achieve both a reduced feeling of threat and persistent treatment engagement.
CI  - (c) 2023. The Author(s).
FAU - Hidaka, Tomoo
AU  - Hidaka T
AUID- ORCID: 0000-0003-2987-4804
AD  - Department of Hygiene and Preventive Medicine, Fukushima Medical University, 
      Hikarigaoka 1, Fukushima, Fukushima, 9601295, Japan. thidaka@fmu.ac.jp.
FAU - Suzuki, Rieko
AU  - Suzuki R
AD  - Koriyama City Public Health Center, 15-1, Asahi 2, Koriyama, Fukushima, 9638024, 
      Japan.
FAU - Hashimoto, Katsue
AU  - Hashimoto K
AD  - Koriyama City Public Health Center, 15-1, Asahi 2, Koriyama, Fukushima, 9638024, 
      Japan.
FAU - Inoue, Mariko
AU  - Inoue M
AD  - CMR Development Division, Novo Nordisk Pharma Ltd., 2-1-1, Marunouchi, 
      Chiyoda-ku, Tokyo, 1000005, Japan.
FAU - Terada, Yukiko
AU  - Terada Y
AD  - CMR Development Division, Novo Nordisk Pharma Ltd., 2-1-1, Marunouchi, 
      Chiyoda-ku, Tokyo, 1000005, Japan.
FAU - Endo, Shota
AU  - Endo S
AD  - Department of Hygiene and Preventive Medicine, Fukushima Medical University, 
      Hikarigaoka 1, Fukushima, Fukushima, 9601295, Japan.
FAU - Kakamu, Takeyasu
AU  - Kakamu T
AD  - Department of Hygiene and Preventive Medicine, Fukushima Medical University, 
      Hikarigaoka 1, Fukushima, Fukushima, 9601295, Japan.
FAU - Gunji, Mariko
AU  - Gunji M
AD  - Koriyama City Public Health Center, 15-1, Asahi 2, Koriyama, Fukushima, 9638024, 
      Japan.
FAU - Abe, Koichi
AU  - Abe K
AD  - Igarashi Clinic of Medicine and Surgery, 12-7, Namiki 2, Koriyama, Fukushima, 
      9638026, Japan.
FAU - Fukushima, Tetsuhito
AU  - Fukushima T
AD  - Department of Hygiene and Preventive Medicine, Fukushima Medical University, 
      Hikarigaoka 1, Fukushima, Fukushima, 9601295, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230620
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC10363091
OTO - NOTNLM
OT  - Content analysis
OT  - Fear-based strategy
OT  - Future perspective
OT  - Invasiveness
OT  - Persistent treatment
OT  - Psychological insulin resistance
OT  - Text-mining
COIS- Mariko Inoue and Yukiko Terada have been employed by and had a stock ownership of 
      Novo Nordisk Pharma Ltd. Tomoo Hidaka, Rieko Suzuki, Katsue Hashimoto, Shota 
      Endo, Takeyasu Kakamu, Mariko Gunji, Koicko Abe, and Tetsuhito Fukushima declare 
      that they have no conflict of interest.
EDAT- 2023/06/21 01:07
MHDA- 2023/06/21 01:08
PMCR- 2023/06/20
CRDT- 2023/06/20 23:31
PHST- 2023/04/26 00:00 [received]
PHST- 2023/06/07 00:00 [accepted]
PHST- 2023/06/21 01:08 [medline]
PHST- 2023/06/21 01:07 [pubmed]
PHST- 2023/06/20 23:31 [entrez]
PHST- 2023/06/20 00:00 [pmc-release]
AID - 10.1007/s13300-023-01433-1 [pii]
AID - 1433 [pii]
AID - 10.1007/s13300-023-01433-1 [doi]
PST - ppublish
SO  - Diabetes Ther. 2023 Sep;14(9):1437-1449. doi: 10.1007/s13300-023-01433-1. Epub 
      2023 Jun 20.